LV10579B - Pharmaceutical composition - Google Patents

Pharmaceutical composition Download PDF

Info

Publication number
LV10579B
LV10579B LVP-94-151A LV940151A LV10579B LV 10579 B LV10579 B LV 10579B LV 940151 A LV940151 A LV 940151A LV 10579 B LV10579 B LV 10579B
Authority
LV
Latvia
Prior art keywords
diethoxy
dione
purine
monohydrate
dihydro
Prior art date
Application number
LVP-94-151A
Other languages
English (en)
Latvian (lv)
Other versions
LV10579A (lv
Inventor
Ender Ferenc
Furesz Jozsef
Rosivall Laszlo
Schweitzer Katalin
Original Assignee
Chinoin Gyegyszer S Vegy Szeti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chinoin Gyegyszer S Vegy Szeti filed Critical Chinoin Gyegyszer S Vegy Szeti
Publication of LV10579A publication Critical patent/LV10579A/xx
Publication of LV10579B publication Critical patent/LV10579B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
LVP-94-151A 1993-08-02 1994-07-29 Pharmaceutical composition LV10579B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU9302229A HUT68560A (en) 1993-08-02 1993-08-02 The use of xantine derivatives for promotion of healing of operative lesions

Publications (2)

Publication Number Publication Date
LV10579A LV10579A (lv) 1995-04-20
LV10579B true LV10579B (en) 1995-10-20

Family

ID=10983853

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-94-151A LV10579B (en) 1993-08-02 1994-07-29 Pharmaceutical composition

Country Status (11)

Country Link
US (1) US5516778A (de)
EP (1) EP0640342A3 (de)
JP (1) JPH07145059A (de)
KR (1) KR950005307A (de)
CA (1) CA2129274A1 (de)
CZ (1) CZ185394A3 (de)
HU (1) HUT68560A (de)
LV (1) LV10579B (de)
RU (1) RU94028283A (de)
SK (1) SK92194A3 (de)
ZA (1) ZA945752B (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6436425B1 (en) 1988-11-16 2002-08-20 Mdv Technologies, Inc. Method and non-gelling composition for inhibiting post-surgical adhesions
WO1998029127A1 (en) * 1995-10-06 1998-07-09 Mdv Technologies, Inc. Method and non-gelling composition for inhibiting post-surgical adhesions
KR20100121527A (ko) 2008-02-29 2010-11-17 콘서트 파마슈티컬즈, 인크. 치환된 잔틴 유도체
US20110053961A1 (en) 2009-02-27 2011-03-03 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
WO2013013052A1 (en) 2011-07-19 2013-01-24 Concert Pharmaceuticals, Inc. Substituted xanthine derivatives
IN2014DN08443A (de) 2012-04-13 2015-05-08 Concert Pharmaceuticals Inc
US20170216296A1 (en) 2014-04-18 2017-08-03 Concert Pharmaceuticals, Inc. Methods of treating hyperglycemia

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU197207B (en) * 1985-12-04 1989-03-28 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical comprising 1-(3',4'-diethoxybenzyl)-6,7-diethoxy-3,4-dihydro-isoquinolinium-theophylline-7-acetate or its monohydrate as active ingredient

Also Published As

Publication number Publication date
CA2129274A1 (en) 1995-02-03
EP0640342A2 (de) 1995-03-01
JPH07145059A (ja) 1995-06-06
HU9302229D0 (en) 1993-10-28
HUT68560A (en) 1995-04-27
EP0640342A3 (de) 1995-04-19
CZ185394A3 (en) 1995-02-15
ZA945752B (en) 1995-10-25
US5516778A (en) 1996-05-14
SK92194A3 (en) 1995-03-08
LV10579A (lv) 1995-04-20
KR950005307A (ko) 1995-03-20
RU94028283A (ru) 1996-08-27

Similar Documents

Publication Publication Date Title
Cushman et al. Differentiation of Angiotensin–Converting Enzyme (ACE) Inhibitors by Their Selective Inhibition of ACE in Physiologically Important Target Organs
Cushman et al. Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE).
Lim et al. Magnesium deficiency in patients on long-term diuretic therapy for heart failure
US5225401A (en) Treatment of congestive heart failure
EP0730458B1 (de) Verwendung von aldosteronantagonisten zur hemmung von myocardfibrose
US4983598A (en) Pharmaceutical composition containing diltiazem and angiotensin-converting enzyme inhibitor
WO2000064470A1 (en) A pharmaceutical formulation comprising a low molecular weight thrombin inhibitor and its prodrug
JPS63264421A (ja) 高脂質血症治療剤
US6071931A (en) AT1 -receptor antagonists for preventing and treating postischemic renal failure and for protecting ischemic kidneys
LV10579B (en) Pharmaceutical composition
US6586416B2 (en) Methods of treatment using an epithelial sodium channel blocker and an inhibitor of the mineralocorticoid receptor
JP2002527383A (ja) ヒストクロム、並びに急性心筋梗塞及び虚血性心疾患治療におけるその使用
JPH0967252A (ja) ローヤルゼリーに含まれるトランス−１０−ヒドロキシ−デセン酸を有効成分とするアンジオテンシン転換酵素阻害剤及びインスリン様作用剤
JP2001506277A (ja) マグネシウム吸収を高め、アテローム性動脈硬化症を防ぐ方法
Villamil et al. A double-blind study to compare the efficacy, tolerance and safety of two doses of the angiotensin converting enzyme inhibitor ramipril with placebo
UA61955C2 (en) Novel salts of bpc-peptides with organoprojective activity, a process for preparing and use thereof in therapy
EP0207505A2 (de) Verwendung eines Prenylketons zur Herstellung eines Arzneimittels gegen Gastritis
JPH02255624A (ja) 血小板凝集抑制剤
Gale et al. Primary aldosteronism: a case with severe hypertension
AU749673B2 (en) Use of glycosaminoglycans for producing pharmaceutical preparations for treating diabetes-associated diseases of the eye
JPS63107939A (ja) 抗貧血剤
KR20020037140A (ko) 지질 저하 활성을 갖는 플라보노이드를 포함하는 터몹시스알터니플로라 추출물 및 이를 유효 성분으로 하는 약학적조성물
RU2003979C1 (ru) Способ прогнозировани течени послеоперационного периода у больных врожденными пороками сердца
TWI785853B (zh) 組成物用於治療高血壓的用途
DK169304B1 (da) Anvendelse af ponalrestat til fremstilling af et urinsyresænkende lægemiddel